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1. Introduction
The nomenclature “Vasculitis” is a pathologic term that refers to an inflammatory process 
affecting a vessel wall, the inflammation leads to fibrinoid necrosis and vessel wall damage. 
The inflammatory process takes place in either isolate or mixed forms synchronously or 
sequentially with interruption of the blood flow to vital tissues giving protean presentations. 
It is the territorial and developmental characteristics of the vessels that determine the patterns 
and the after comings of the pathology. The etiology of the disease remains largely unex-
plored. On the one hand, when vessel inflammation exists as an independent pathology, it is 
usually classified as primary vasculitis; on the other hand, if vessel inflammation develops as 
a part of an existing primary pathology, it is classified as secondary vasculitis. An evidence-
based approach to the classification of vasculitis has been challenged by the uniquely hetero-
geneous pattern of the inflammatory process, the confusing serology, non-uniform response 
to therapy, and poorly identified prognostic markers [1].
In 1994, the Chapel Hill Consensus Conference designed a nomenclature classification of 
vasculitis based on the size of the affected vessel [2, 3]. Clinical and research evidences 
have proven that considering vessel caliber as the sole determining factor for a multiplic-
ity of heterogeneous consequences seems a rather simple hypothesis for a more complex 
pathology. The disappearance of specific clinic-pathologic variants of vasculitis that are 
commonly encountered in practice was one important shortcoming of the 1994 classifica-
tion. With advancing research and disclosure of a number of potential developmental 
and pathogenic interplayers provided an in-depth understanding of the disease. Scientific 
research illustrated that the vascular developmental patterns and the territorial distribu-
tion are major determinants of vessel wall reactivity to inflammation, endothelial antigenic 
cross talks, and response to inflammatory mediators. Vascular beds in different organs vary 
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with respect to organ function in multiple aspects including morphology and function of 
the endothelial cells, intercellular junctions, the subendothelial matrix, the types of matrix 
components (including collagens, laminins, nidogens, fibronectin, vitronectin, and fibrillins), 
membrane proteins (adhesion molecules and Toll-like receptors—TLRs), and the pericytes 
that surround the endothelial cells. Such variations influence cell proliferation, migration, 
differentiation, transvascular passage of solutes and cellular diapedesis, chemotaxis, and tis-
sue injury-response patterns. Microvascular diversities have been even seen within the same 
organ with the kidney featuring one good model [1–4].
In 2012, the Chapel Hill Consensus Conference went for revision of the 1994 classification 
to provide more precise classification of vasculitis with illustration of the different forms of 
vasculitis encountered in practice considering the nature of the pathology, the vessel size, and 
the etiology [5] Figure 1.
Definitions for vasculitides adopted by the 2012 International Chapel Hill Consensus 
Conference on the Nomenclature of Vasculitides (CHCC2012) [5, 6]:
I. Large-vessel vasculitis (LVV): vasculitis predominantly affecting large arteries (the aorta 
and its major branches); however, any size may be affected. It includes two main subtypes:
a. Takayasu arteritis (TAK): granulomatous arteritis affecting the aorta and/or its major 
branches in patients younger than 50 years. The consensus retained the eponym 
“Takayasu” against the proposed non-eponymous term “early onset granulomatous 
aortitis/arteritis” being more effective than any alternative.
b. Giant cell arteritis (GCA): granulomatous arteritis, usually affecting the aorta and/or 
its major branches, with a higher predilection for the branches of the carotid and 
vertebral arteries usually in patients older than 50 years and commonly associated 
with polymyalgia rheumatic. The disease often involves the temporal artery with the 
term “temporal arteritis” being commonly in use; however, not all patients with GCA 
have temporal artery involvement.
II. Medium-vessel vasculitis (MVV): vasculitis predominantly affecting medium-sized arter-
ies defined as the main visceral arteries and their branches, and any size artery may be 
affected by the pathology. Inflammatory aneurysmal dilatations and arterial narrowing 
are common.
a. Polyarteritis nodosa (PAN): necrotizing arteritis of the medium or small arteries or 
vasculitis in arterioles, capillaries, or venules, not associated with antineutrophil cyto-
plasmic antibodies (ANCAs).
b. Kawasaki disease (KD): arteritis involving the medium- and small-sized arteries. The 
disease occurs in infants and young children presenting with mucocutaneous lymph 
node syndrome. Coronary arteritis remains a hallmark being frequently involved, 
while the aorta and large arteries may get involved.
III. Small-vessel vasculitis (SVV): vasculitis predominantly affecting small vessels defined as 
small intraparenchymal arteries, arterioles, capillaries, and venules. Similarly, medium 
arteries and veins may be affected.
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a. ANCA-associated vasculitis (AAV): necrotizing vasculitis, with few or no immune 
deposit, that is, pauci-immune necrotizing vasculitis, predominantly affecting the 
small vessels (i.e., capillaries, venules, arterioles, and small arteries), usually associ-
ated with antibodies to myeloperoxidase (MPO) or proteinase 3 (PR3) classified as 
either MPO-ANCA or PR3-ANCA, although not all the patients with this form of 
necrotizing vasculitis are ANCA positive.





1. Microscopic polyangiitis (MPA): necrotizing vasculitis, with few or no immune 
deposits, predominantly affecting small vessels (i.e., capillaries, venules, or arte-
rioles). Necrotizing pauci-immune arteritis involving small- and medium-sized 
arteries and necrotizing glomerulonephritis and pulmonary capillaritis are fre-
quent presentations, while granulomatous inflammation is absent.
2. Granulomatosis with polyangiitis (Wegener’s) (GPA): necrotizing granulomatous 
vasculitis affecting predominantly from small to medium vessels (e.g., capillar-
ies, venules, arterioles, arteries, and veins) usually involving the upper and lower 
respiratory tract. Necrotizing glomerulonephritis is common.
3. Eosinophilic granulomatosis with polyangiitis (Churg-Strauss) (EGPA): EGPA is an 
eosinophil-rich necrotizing granulomatous inflammation predominantly affecting 
from small to medium vessels often involving the respiratory tract and associated 
with asthma and eosinophilia. Nasal polyps are common. ANCA is more frequent 
when glomerulonephritis is present. The eponym “Churg-Strauss syndrome” was 
replaced by “EGPA” in part to achieve nomenclature symmetry with MPA and GPA.
b. Immune complex vasculitis: vasculitis predominantly affecting small vessels (i.e., capil-
laries, venules, arterioles, and small arteries) with moderate to marked immune com-
plex deposits within vessel wall. Glomerulonephritis is frequent.
c. Anti-glomerular basement membrane (anti-GBM) disease: vasculitis affecting glomerular 
capillaries, pulmonary capillaries, or both, with GBM deposition of anti-GBM autoanti-
bodies. Lung involvement causes pulmonary hemorrhage, and renal involvement causes 
glomerulonephritis with necrosis and crescents.
d. Cryoglobulinemic vasculitis (CV): vasculitis with immune deposits affecting small ves-
sels (predominantly capillaries, venules, or arterioles) and associated with circulating 
cryoglobulins. Skin, glomeruli, and peripheral nerves are often involved.
e. IgA vasculitis (Henoch-Schönlein) (IgAV): vasculitis, with IgA1-dominant immune 
deposits, affecting small vessels (predominantly capillaries, venules, or arterioles). 
Skin, gastrointestinal tract, and joints are frequently involved. Glomerulonephritis 
indistinguishable from IgA nephropathy may occur.
f. Hypocomplementemic urticarial vasculitis (HUV) (anti-C1q vasculitis): vasculitis affecting 
small vessels (i.e., capillaries, venules, or arterioles) manifesting by urticaria and associ-
ated with hypocomplementemia and anti-C1q antibodies. Glomerulonephritis, arthri-
tis, obstructive pulmonary disease, and ocular inflammation are common presentations.
IV. Variable vessel vasculitis (VVV): a form of vasculitis that can affect vessels of any size (small, 
medium, and large) and type (arteries, veins, and capillaries).
a. Behcet’s disease (BD): vasculitis that can affect arteries or veins of variable calibers, 
characterized by recurrent oral and/or genital aphthous ulcers and accompanied by 
cutaneous, ocular, articular, gastrointestinal, and/or central nervous system inflamma-
tory lesions. Small vessel vasculitis, thromboangiitis, thrombosis, arteritis, and arterial 
aneurysms may occur.
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b. Cogan’s syndrome (CS): Cogan’s syndrome is a form of vasculitis that can affect vessels 
of variable sizes. The disease leads to arteritis (affecting small, medium, or large arter-
ies), aortitis, aortic aneurysms, and aortic and mitral valvulitis. Clinically presents by 
ocular inflammatory lesions, including interstitial keratitis, uveitis, and episcleritis, 
and inner ear disease, including sensorineural hearing loss and vestibular dysfunction.
V. Single-organ vasculitis (SOV): vasculitis in arteries or veins of any size in a single organ 
that has no features that indicate that it is a limited expression of a systemic vasculitis. 
Vasculitis may be unifocal or multifocal/diffuse within the same organ. Usually defined 
in terms of the involved organ and vessel type, for example, cutaneous small vessel vas-
culitis, testicular arteritis, and central nervous system vasculitis. Some patients originally 
diagnosed as SOV may develop additional disease manifestations that warrant redefin-
ing the case as one of the systemic vasculitides, for example, cutaneous arteritis later 
becoming systemic polyarteritis nodosa, and so on.
VI. Vasculitis associated with systemic disease: vasculitis that is associated with and/or may be 
secondary to a systemic disease. The diagnosis should specify the systemic disease, for 
example, rheumatoid vasculitis, lupus vasculitis, and so on.
VII. Vasculitis associated with probable etiology: vasculitis that is associated with a probable specific 
etiology, for example, hydralazine-associated microscopic polyangiitis, hepatitis B virus-
associated vasculitis, hepatitis C virus-associated cryoglobulinemic vasculitis, and so on.
In this book, the authors will provide and discuss an update on specific clinic-pathologic 
(Figure 2) subtypes of vasculitis including the pauci-immune vasculitis and immune 




complex-mediated small vessel vasculitis with a special focus on renal disease among other 
vasculitis-related pathologies.
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